Baricitinib inhibits structural joint damage progression in patients with rheumatoid arthritis-a comprehensive review.

Arthritis Res Ther · 2021 · PMC7784289 · PMID 33397481

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceno p-value reported

Changes with baricitinib 2 mg were smaller than those with placebo, but the differences did not reach statistical significance.

also in 111,027 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.